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Fms-Like Tyrosine Kinase 3 Ligand Recruits Plasmacytoid
Dendritic Cells to the Brain1
James F. Curtin*#, Gwendalyn D. King*, Carlos Barcia*, Chunyan Liu*, François X. Hubert†,
Carole Guillonneau†, Régis Josien†, Ignacio Anegon†, Pedro R. Lowenstein*,‡,2, and Maria
G. Castro*,‡,2
* Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048
† Institut National de la Sante et de la Recherche Medicale, Unité 437, and Institut de
Transplantation et de Recherche en Transplantation, Nantes, France
‡ Department of Molecular and Medical Pharmacology and Department of Medicine, David Geffen
School of Medicine, University of California, Los Angeles, CA 90048
#Current Address: School of Biological Sciences, Dublin Institute of Technology, Dublin 8, Ireland

Abstract
The lack of professional afferent APCs in naive brain parenchyma contributes to the systemic immune
ignorance to Ags localized exclusively within the brain. Dendritic cells (DCs) appear within the brain
as a consequence of inflammation, but no molecular mechanisms accounting for this influx have
been described. In this study we demonstrate that Fms-like tyrosine kinase 3 ligand (Flt3L) recruits
plasmacytoid DCs (pDCs; >50-fold; p < 0.001) to the brain parenchyma. These pDCs expressed IFNα, the hallmark cytokine produced by pDCs, indicating recruitment and activation in situ of bona
fide pDCs within the brain parenchyma. Flt3L did not increase the numbers of conventional DCs,
macrophages, or B, T, NK, NKT, or microglial cells within the brain. Our data demonstrate that Flt3L
reconstitutes a crucial afferent component of the immune response, namely, professional APCs
within the brain parenchyma, and this could counteract the intrinsic systemic immune ignorance to
Ags localized exclusively within the brain.

Antigenic epitopes localized exclusively within the brain parenchyma (i.e., brain proteins,
viruses, and tumors) do not prime a systemic immune response (1–3). Upon careful Ag delivery
selectively to the brain parenchyma of healthy rats and mice, neither systemic activation nor
tolerance against such Ags has been observed. However, systemically activated T cells display
normal effector T cell function toward Ags localized in the brain, e.g., in autoimmune multiple
sclerosis or in animals experimentally immunized against viral or tumor Ags localized within
the brain (1,3,4). This implies that immune ignorance to brain Ags is due to defects in the
afferent limb and not the efferent limb of the adaptive immune system.

The brain parenchyma lacks two central cellular and anatomical components necessary for
priming an immune response, i.e., dendritic cells (DCs)3 and classical lymphatic outflow
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channels (5,6). Therefore, the neuroanatomy of the brain immune components explains the
particular characteristics of immune responses against brain Ags. DCs are unique in their ability
to phagocytose foreign Ags, migrate to secondary lymphoid structures, display antigenic
epitopes to naive T cells, and elicit potent T cell-dependent immune responses (7).
Conventional DCs (cDCs) and plasmacytoid DCs (pDCs) can be found in the cerebrospinal
fluid (CSF), choroid plexi, and brain meninges in healthy animals and healthy humans. The
noninflamed brain parenchyma, unlike the ventricles, choroid plexi, and meninges, is devoid
of DCs. However, resident brain microglia, perivascular macrophages, endothelial cells, and
astrocytes can all increase the expression of MHC class II (MHC II) and MHC I during brain
inflammation, suggesting that they display Ags to the activated arm of the immune system
through interaction with Ag-specific, primed CD4+ and CD8+ T cells, but not to naive T cells
(8). None of these cells, however, has been conclusively shown to take up Ags, leave the brain
parenchyma, carry the Ag to cervical lymph nodes, or present antigenic epitopes to naive T
cells.

DCs are present in the brain during chronic inflammation, such as in multiple sclerosis (MS)
(9,10) and experimental autoimmune encephalitis (EAE) (11,12), and MHC II expression on
CD11c+ DCs was found to be both sufficient and necessary for complete generation of the
clinical disease, underscoring the importance of CD11c+ DCs in presenting brain Ag to T cells
(13). OX62+ DCs were found to infiltrate the brain parenchyma in response to an excitotoxic
inflammatory lesion in the rat striatum. Depletion of bone marrow, but not perivascular- and
meningeal-derived macrophages, abrogated this effect, suggesting that OX62+ DCs were
derived from blood-borne immune cells (14). DCs can also infiltrate the brain parenchyma in
response to the chronic presence of prions in the brain (15). However, little is currently known
about the molecular mechanisms mediating DC infiltration or differentiation within the brain
parenchyma during inflammation.

In this study we demonstrate that elevated expression of Fms-like tyrosine kinase 3 ligand
(Flt3L) in the brain is sufficient to selectively recruit and activate pDCs, but not other immune
cells, in the brain parenchyma. Flt3L is constitutively expressed by cells resident in the brain,
suggesting that aberrant expression may increase the capacity of the brain to present Ag to
naive, Ag-specific T cells. We have recently shown that Flt3L expression in intracranial tumors
induced a robust, CD4-dependent, antitumor immune response in a rat model of brain cancer
when used in combination with the conditionally cytotoxic gene thymidine kinase (16). It has
been recently shown that systemic administration of Flt3L increased DCs in the brain meninges
and augmented the severity of clinical symptoms in a mouse model of MS (13). Inhibition of
Flt3 signaling using the small drug inhibitor of Flt3R CEP-701 significantly decreased
autoreactive immune cells and improved clinical symptoms in a mouse model of established
EAE (17).

In summary, our results demonstrate that Flt3L expression in the brain significantly,
selectively, and specifically increases the number of pDCs in the brain parenchyma. This could
overcome immune ignorance of brain Ags by promoting presentation of brain-derived Ag to
T cells. The recent description of cDCs being able to migrate from the CSF to the cervical
lymph nodes (18) and other supporting evidence from Carson et al. (19) and Pashenkov et al.
(20) indicate that although the brain lacks classical lymphatic outflow channels, it may be able
to compensate for this during disease states that cause brain inflammation.

3Abbreviations used in this paper: DC, dendritic cell; cDC, conventional DC; CFS, cerebrospinal fluid; EAE, experimental autoimmune
encephalitis; Flt3L, Fms-like tyrosine kinase 3 ligand; hs, human soluble; β-Gal, β-galactosidase; GFAP, glial fibrillary acidic protein;
MBP, myelin basic protein; MHC I, MHC class I; MS, multiple sclerosis; pDC, plasmacytoid DC; RAd5, recombinant adenovirus type
5.
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Materials and Methods
Construction of adenoviral vectors
β-Galactosidase (β-Gal) and Flt3L were expressed in the brains of Lewis rats using firstgeneration, replication-defective, recombinant adenovirus type 5 (RAd5) vectors expressing
transgenes under transcriptional control of the human CMV major intermediate early promoter
within the E1 region. RAd0 is a first-generation adenoviral vector that does not contain any
transgene and is used to control total virus load. RAd35 (an adenovirus encoding β-Gal) and
RAdFlt3L (an adenovirus encoding human soluble Flt3L) have been described previously
(21,22). The methods for adenoviral generation, production, characterization, and scale up and
for viral vector purification have been previously described (23,24). The titers were 6.55 ×
1011 IU/ml for RAd0, 1.64 × 1011 IU/ml for RAd35, and 6.55 × 1011 IU/ml for RAd-human
serum Flt3L. All viral preparations used were free from replication-competent adenovirus and
LPS contamination (24). Viruses were diluted in sterile saline for intracranial injection.

Production of anti-Flt3L Abs
We generated rabbit Abs specific for human soluble Flt3L. Briefly, New Zealand White rabbits
were immunized three times (14 days apart) with purified peptide CETVFHRVSQDGLDL
coupled with keyhole limpet hemocyanin (New England Peptides). This peptide sequence is
present in soluble, but not bound, isoforms of human Flt3L and is not conserved with rodent
Flt3L isoforms. After the third immunization, the titer of the Ab was verified by ELISA
(1/64,000), and whole serum was recovered for characterization by Western blot and
immunohistochemistry.

Intracranial injection of adenoviral vectors
Male Lewis rats (225–250 g in body weight) were purchased from Harlan Sprague Dawley.
All sentinel rats housed in the same colony were specific pathogen free. Animals were
anesthetized with ketamine and medatomidine and placed in a stereotaxic frame. The rats were
then injected in the right striatum (+1 mm forward from bregma, +3 mm lateral, and −4 mm
ventral from the dura) with saline or adenoviral vectors diluted in saline. A hole was drilled in
the skull, and the vectors were administered in a volume of 2 μl using a 10-μl Hamilton syringe
with a 26-gauge needle. A small pocket was created before the deposition of virus by holding
the needle 0.2 mm below the stated ventral coordinates for 1 min before moving up to the stated
coordinates and slowly injecting the virus over a period of 2 min. The needle was left in place
for an additional 5 min before being carefully removed from the brain.

Flow cytometry of brain mononuclear cells
Rats were perfused with 100 ml of heparinized Tyrode’s solution 1 or 5 days after intracranial
injection of virus or saline. Splenocytes were harvested, and RBC were removed using
ammonium chloride and potassium solution. Brains were separated from the meninges and
removed from the skull. The area around the injection site was dissected, taking care to avoid
the ventricles (Fig. 1A). This tissue was then diced with a razor blade before homogenization
in RPMI 1640 medium (Invitrogen Life Technologies) using a glass Tenbroeck homogenizer.
Mononuclear cells were purified from brain tissue by centrifugation through a Percoll gradient;
mononuclear cells migrate to the interface between 30 and 70% Percoll. Cells were counted
and labeled with Abs for analysis by flow cytometry. Briefly, cells were resuspended at 5 ×
105 cells/ml in 1 ml of cell surface staining buffer (0.1 M PBS without Ca2+ and Mg2+ and
with 1% FBS and 0.1% sodium azide). Cells were centrifuged, and the supernatant was
discarded. The cells were resuspended in 100 μl of cell surface staining buffer containing the
combinations of Abs described below and incubated for 30 min at 4°C. After this incubation,
the samples were washed in 1 ml of cell surface staining buffer and analyzed by flow cytometry.
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All Abs used were purchased from BD Pharmingen unless otherwise indicated. CD3-FITC,
CD45R (B220)-PE and CD4-PE/Cy5 were used to distinguish B cells and pDCs. Samples were
stained with CD11c-FITC (Serotec), CD45-PE, and CD4-PE/Cy5 to identify cDCs and resident
brain microglia. CD3-FITC, CD8a-PE, and CD4-PE/Cy5 were used to label CD4+ and
CD8+ T cells. CD3-FITC and CD161a-PE were used to analyze NK cells, NKT cells, and total
T cells. CD11b-FITC and CD45-PE were used to stain for macrophages.

Immunohistochemistry
Animals were killed by perfusion/fixation with heparinized Tyrode’s solution (132 mM NaCl,
1.8 mM CaCl2, 0.32 mM NaH2PO4, 5.56 mM glucose, 11.6 mM NaHCO3, and 2.68 mM KCl),
followed by 4% paraformaldehyde in PBS at the desired time points. Brains were removed for
immunohistochemical analysis. Fifty-micrometer-thick coronal sections of fixed brains were
cut using a Vibratome (Leica VT10005), and free-floating immunohistochemistry was
performed as described elsewhere (22,25). Briefly, rabbit anti-Flt3L was used at a
concentration of 1/1000 for immunohistochemistry and immunofluorescence. An Axioplan II
microscope and imaging software (Zeiss) were used to obtain images of 3,3′diaminobenzidine-stained cells. For immunofluorescence labeling, rabbit anti-Flt3L was
detected using anti-rabbit Alexa 488 (1/1000; Molecular Probes). Guinea pig anti-glial
fibrillary acidic protein (anti-GFAP; 1/1000, Advanced Immunochemical) was detected using
anti-guinea pig Alexa 647 (1/800; Molecular Probes). Mouse anti-ED1 (1/1000; Serotec),
mouse antineuronal-specific nuclear protein (1/1000; Chemicon International), and mouse
anti-myelin basic protein (anti-MBP; 1/1000; Chemicon International) were detected with antimouse Alexa 594 (1/800; Molecular Probes). Confocal images were taken using a Leica
DMIRE2 microscope with a ×63 oil objective and Leica confocal software. Confocal images
of each section were taken at a 0.5-μm-thick resolution and were overlaid to produce the final
images.

RT-PCR from rat brain tissue homogenate
RNA was extracted from rat brain tissue, isolated from striatum tissue dissected as indicated
in Fig. 1A and injected 1 or 5 days previously with saline, RAd35, or RAdFlt3L using RNABee
reagent (Tel-Test). An RT reaction was set up using 0.5 μg of RNA in each sample and oligo
(dT) primer with Moloney murine leukemia virus reverse transcriptase. Primers specific for
GAPDH (forward, 5′-ACC ACA GTC CAT GCC ATC AC-3′; reverse, 5′-TCC ACC ACC
CTG TTG CTG TA-3′), IFN-α (forward, 5′-CAG CAG ATC CAG AAG DCT CAA RC-3′;
reverse, 5′-CAG GCA CAG GGR CTG TGT TT-3′; D = A, G, or T; R = A or G), IFN-α
(forward, 5′-TGC TGT GCT TCT CCA CCA CT-3′; reverse, 5′-TAG TCT CAT TCC ACC
CAG TGC T-3′), TLR7 (forward, 5′-TTT CCC AGA GCA TAC AGC TCA G-3′; reverse 5′CAC TCA AGG ACA GAA CTG CTG C-3′), TLR9 (forward, 5′-CCT GGC ACA CAA TGA
CAT TCA-3′; reverse, 5′-TAA AGG TCC TCC TCG TCC CA-3′), MHC II (forward, 5′-CCC
CAG ATG CCA ATG TGA-3′; reverse, 5′-TCA GAT GCT GTC ACA GCA-3′), and CD80
(forward, 5′-CTG CTG GTT GGT CTA TTC CA-3′; reverse, 5′-TCA GAT TCA GGA TCC
TGG GAA-3′) were subsequently used to amplify target sequences from the cDNA using PCR.
An annealing temperature of 55°C was used, and the number of cycles is indicated in the figure
legends. DNA bands were separated using agarose gel electrophoresis and were visualized
using a gel documentation system (Alpha Innotech).

Purification of pDCs from brain and spleen
Brain tissue from 30 rat brain hemispheres injected 5 days previously with RAdFlt3L was
processed as described above to isolate mononuclear cells. These cells were pooled and stained
with CD3-FITC, CD45R-PE, and CD4-PE/Cy5. Spleen cells from a single rat injected with
RAdFlt3L 5 days previously were also purified and treated with ammonium chloride and
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potassium solution to remove erythrocytes before staining with CD3-FITC, CD45R-PE, or
CD4-PE/Cy5. The pDCs were sorted using an Ario cell sorter (DakoCytomation), gating live
leukocytes for CD3−, CD45+, and CD4+. We isolated 10,000 pDCs from the pooled brain
mononuclear cells. We also isolated 10,000 pDCs from the spleen as a positive control sample.
Five thousand spleen pDCs and 5000 brain pDCs were stimulated with 20 μg/ml CpG for 3 h
in X-Vivo10 medium (Cambrex). The remaining 5000 pDCs from spleen and brain were
incubated for 3 h in X-Vivo10 medium without CpG. Total RNA was isolated from samples,
as outlined above, using RNAbee reagent, and 50 μg of tRNA was used as the carrier nucleic
acid during isopropanol and ethanol precipitation steps. RT-PCR was performed as outlined
previously.

Flt3L ELISA
Blood was collected and allowed to coagulate before centrifugation to isolate serum. Animals
were killed by terminal perfusion with heparinized Tyrode’s solution. Brains were separated
from the meninges and removed from the skull. Blocks of brain tissue around the injection site
were homogenized into a single-cell suspension. Multiple freeze-thaw cycles were used to
extract cellular protein, which was separated from insoluble tissue by centrifugation and stored
on ice until use. Quantikine ELISA kits for rat Flt3L and human Flt3L were purchased from
R&D Systems and were used as recommended in the manufacturer’s instructions.

Statistical analyses
Statistical analysis was performed using one-way nonparametric ANOVA to compare all
samples. Grubb’s test for outliers was used to remove extraneous data points, and Dunn’s
multiple comparison was used to compare all samples against saline-injected animals. A
difference of p < 0.05 was considered significant.

Results
Overexpression of Flt3L within brain: levels and cell type-specific expression
It was important to assess the levels as well as the cell types within the brain that expressed
human Flt3L after injection of RAdFlt3L and compare them with the levels of endogenous
rodent Flt3L. We used purified recombinant human and mouse Flt3L to confirm that human
and rodent Flt3L ELISA kits (R&D Systems) were species specific (Fig. 1B). We assessed by
ELISA the concentrations of transgene and endogenous Flt3L expressed in both brain and
serum of rats 5 days after intracranial injection of adenoviral vectors. As expected, a high
concentration of human Flt3L (>30 pg/mg total brain protein) was observed in the brains of
rats injected with RAdFlt3L, whereas no expression was detected in saline- and control virusinjected samples. The concentration of endogenous rat Flt3L expressed in the brain of salineinjected animals (<2 pg/mg total brain protein) was calculated to be >15 times lower than that
of human Flt3L transgene in the brains of rats infected with RAdFlt3L, and endogenous levels
of Flt3L expression did not change in response to the injection of either RAd35 or RAdFlt3L
(Fig. 1C). We also detected >200 pg/ml human Flt3L transgene in rat sera 5 days after infection
with RAdFlt3L, indicating that significant quantities of soluble human Flt3L expressed within
the brain diffused across the blood-brain barrier and entered the systemic circulation.
Endogenous Flt3L expression was not found to change in response to either RAdFlt3L or
RAd35, and serum concentrations of human Flt3L in RAdFlt3L-infected animals were >10fold higher than those of endogenous rat Flt3L (<20 pg/ml; Fig. 1D). These results suggest that
increasing the serum concentration of Flt3L by 10-fold (200 pg/ml) is insufficient to
significantly expand populations of either pDCs or cDCs in the rat spleen.

Next, we determined which cell types within the brain expressed human Flt3L after intracranial
injection of RAdFlt3L. We raised an Ab against human soluble (hs) Flt3L using an epitope not
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present on any rodent or bound human isoform of Flt3L. We tested the specificity of the
antiserum for human soluble Flt3L in HEK 293 cells transfected with the human and mouse
isoforms of Flt3L (Fig. 1E). Preincubation with a blocking peptide completely blocked
immunoreactivity, confirming that the antiserum was specifically binding the Ag against which
it was raised (data not shown). We used confocal microscopy to demonstrate that human Flt3L
expression in the brain was only evident within the striatum and was predominantly associated
with GFAP, a marker of astrocytes (~90%), and MBP, a protein selectively expressed by
oligodendrocytes in the brain (~10%; Fig. 1F).

Flt3L increases a putative pDC population (CD3−CD45R+CD4+), but not cDCs, in brain
parenchyma
The brain parenchyma is usually devoid of mature DCs except during brain inflammation, e.g.,
injection of LPS (26), intracerebral viral infections, or autoimmune diseases (27). It is believed
that the absence of a local lymphatic system and resident DCs capable of phagocytosing local
Ags and migrating to lymphatic structures, where they can present antigenic epitopes to naive
T cells, is a major factor that prevents the induction of Ag-specific immune responses after
careful injection of infectious particulate Ag into brain parenchyma (2,4). We hypothesized
that the expression of Flt3L in the striatum would induce the migration and differentiation of
DC populations within the brain, because Flt3L is sufficient to promote all stages of DC
differentiation from precursors. Infiltrating mononuclear cells in the brain were quantified in
a 2-mm3 cube of brain tissue surrounding the injection site, carefully dissected to avoid
including the ventricular system that constitutively contains DCs (Fig. 1A).

We found that the average number of pDCs (CD3−CD4+CD45R+) in brain parenchyma
increased >50-fold after Flt3L was expressed in the brain for 5 days compared with that after
saline only ( p < 0.001; Fig. 2, A and C). The number of pDCs 5 days after the expression of
β-Gal was modestly elevated compared with that after saline; this difference was not
statistically significantly ( p > 0.05). The number of pDC in Flt3L-injected animals was
significantly higher than that in β-Gal-injected animals ( p < 0.001). This indicates that Flt3L,
and not viral particles or other virally expressed proteins, mediated the increase in pDCs in the
brain.

No change in the total number of pDCs was observed after the expression of either Flt3L or
β-Gal for 1 day compared with saline (p > 0.05). Low levels of CD4+ cDC
(CD4+CD11c+CD45+) were found in the brains of rats injected in the striatum 5 days
previously with saline, and this was not increased in rats expressing either β-Gal or hsFlt3L
(Fig. 2, B and D), indicating that elevated expression of Flt3L in the brain specifically recruited
pDCs, and not cDCs. No CD4− cDCs were detected in any brain samples (Fig. 2B and data not
shown). A large population of CD11c+ CD4low immune cells was detected in the brains of
animals treated with saline, and this corresponds to a subpopulation of macrophages, but
treatment with Flt3L did not elevate these immune cells (Fig. 2B and data not shown).

To determine whether leakage of Flt3L from the brain into the general circulation could be
implicated in the increase in pDCs in the brain, we analyzed DC subpopulations in the spleen
after intracranial expression of Flt3L. Although we did detect a significant increase in the serum
levels of Flt3L, we did not detect changes in total pDC numbers (Fig. 2, E and F) or cDC
numbers (Fig. 2, E and G) in the spleen compared with control animals. This suggests that a
high level of intraparenchymal Flt3L, rather than an increase in serum Flt3L, is necessary to
increase pDCs in the brain. Thus, our data indicate that pDCs infiltrating from the CSF or brain
meninges or differentiation of precursor cells within the brain parenchyma are more likely
sources of pDCs observed within the brain parenchyma in response to Flt3L.
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Global expression of IFN-α and TLR7 transiently increases in brain parenchyma in response
to RAdFlt3L
Plasmacytoid pDCs, unlike cDCs, secrete very high concentrations of type I IFN in response
to viral infections and TLR stimulation, 100- and 1000-fold greater than other cells, including
immune cells infected with virus (28). We determined whether the injection of adenoviral
vectors alone into the brain was sufficient to induce the expression of IFN-α in the brain. We
isolated total RNA from the brain striatum 1 and 5 days after the injection of saline, RAd0, or
RAdFlt3L and analyzed the expression of IFN-α. We found that Flt3L expression for 1 day,
but not the control vectors, increased the expression of IFN-α (Fig. 2H) and TLR7 (Fig. 2I).
IFN-β and TLR9 did not increase (Fig. 2, H and I). This global increase in brain expression of
IFN-α and TLR7 in response to Flt3L was transient in nature and returned to basal levels after
5 days (data not shown). However, pDCs were absent from the brain 1 day after the expression
of Flt3L. Thus, the global increase in IFN-α and TLR7 expression 1 day after the expression
of Flt3L originated from a different cell type, e.g., brain perivascular macrophages or microglia,
rather than pDCs.

Putative pDCs (CD3−CD45R+CD4+) isolated from brain constitutively express IFN-α
We verified whether pDCs identified by immunocytochemistry and isolated from the brain
after treatment with Flt3L were capable of producing IFN-α. IFN-α expression in response to
viral or TLR stimulation (100–1,000 times more than normal cells) is a hallmark of immature
pDCs. We used cell sorting to purify CD3−CD45R+CD4+ cells from brain homogenates of rats
5 days after intracranial Flt3L delivery (Fig. 3A). A total of 10,000 pDCs was isolated from 30
brain hemispheres carefully dissected to avoid including any ventricular tissue. We also
purified 10,000 pDCs from the spleen of a rat expressing Flt3L in the brain for 5 days as a
positive control for pDC function. The pDCs isolated from brain and spleen expressed similar
levels of MHC II mRNA, but did not express the costimulatory molecule CD80, indicating
that pDCs in the brain and those isolated from the spleen were immature pDCs (Fig. 3B). MHC
II-expressing cells in the brain were detected in response to Flt3L expression using confocal
microscopy, but CD45R cells did not express detectable levels of MHC II by
immunocytochemistry, suggesting that brain pDCs express MHC II mRNA, but do not express
enough protein at the membrane to be detected by immunocytochemistry. Most likely this
reflects the immature nature of brain pDCs detected (Fig. 3, C and D). Using
immunofluorescent labeling of CD45R to identify the anatomical location of pDCs within the
brain, we found that pDCs were present throughout the striatum of animals treated with Flt3L.
Furthermore, we did not observe any CD45R immunoreactivity in intact meninges from
animals 5 days after expression of either β-Gal (Fig. 3E) or Flt3L (Fig. 3F), indicating that the
expression of Flt3L in brain parenchyma does not induce pDC infiltration or expansion in brain
meninges.

Brain-derived pDCs constitutively expressed IFN-α mRNA (Fig. 3G, left), and incubation with
the TLR9 agonist CpG did not further increase the level of IFN-α expression (Fig. 3G, left).
As a control, pDCs isolated from the spleen did not express detectable levels of IFN-α, and
stimulation with CpG increased the expression of IFN-α mRNA (Fig. 3G, right) as previously
reported in spleen-derived pDCs from humans, mice, and rats (29–31). Our data suggest that
brain-derived pDCs isolated from Flt3L-treated rats had already been activated in vivo, and
TLR9 activation by CpG was unable to further increase the expression of IFN-α.

We used RT-PCR to confirm that both brain- and spleen-derived pDCs expressed TLR9 and
confirmed that TLR9 was expressed in the absence of CpG stimulation (Fig. 3H). Surprisingly,
we found that incubation of spleen-derived pDCs with CpG reduced the expression of TLR9
mRNA (Fig. 3H, right), indicating a possible mechanism by which pDCs can become refractory
to additional stimulation with CpG by down-modulating the expression of components of the
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TLR9 signal transduction pathway, including TLR9. In addition, the expression of TLR9 in
unstimulated, brain-derived pDCs (Fig. 3H, left) was much lower than that of spleen-derived
pDCs (Fig. 3H, right), and this may reflect a previous encounter with TLR agonist in the brain
that induced IFN-α expression and a subsequent refractory phenotype to additional stimulation
with the TLR9 agonist CpG.
pDCs (CD3−CD45R+CD4+) recruited to the brain by Flt3L do not express B cell markers
CD45R/B220 is expressed by pDCs, but not cDCs, and can be used to separate these two
subclasses of DC. CD45R is also expressed on many B cells throughout their development
from the pro-B cell stage onward. Although most B cells do not express CD4, we tried to
establish whether the CD45R+ CD4+ population infiltrating the brain in response to RAdFlt3L
was pDC or a sub-population of B cells. We counterstained CD45R+ cells purified from Flt3Lexpressing brains with Abs that bind to CD4 and either Igκ or Igλ. Igκ and Igλ are L chain
components of the BCR, and cell surface expression of either Igκ or Igλ is first detected on
immature B cells and is thereafter present throughout their subsequent development. We did
not detect any significant population of CD4+CD45R+ cells (Fig. 4A) that also expresses either
Igκ (Fig. 4B) or Igλ (Fig. 4C). This confirms that the infiltrating population of
CD3−CD45R+CD4+ cells was not B cells. Plasma cells are terminally differentiated B cells
that have low surface expression of BCR and stain negatively for Igκ and Igλ by flow cytometry.
However, it is extremely unlikely that we were detecting plasma cells in the brain in response
to Flt3L, because plasma cells are usually sequestered in T cell zones of secondary lymphoid
organs, do not express CD4, require a longer incubation time to develop (i.e., Ag-specific T
cells must first be activated before an Ab-dependent immune response can occur), and do not
express CD45R.

Expression of Flt3L in brain specifically does not increase the numbers of other immune
cells in brain parenchyma
To determine whether increased expression of Flt3L could also promote the expansion of other
immune cell populations within the brain, we analyzed the numbers of B cells, T cells, NK
cells, NKT cells, macrophages, and microglia within the CNS before and after the expression
of Flt3L. No significant increase in other immune cells was observed in response to Flt3L after
expression in the brain for either 1 or 5 days (Fig. 5). Acute inflammation due to injection
trauma or viral vectors was evident 1 day after injection; however, this increase was transient
in nature, and all populations of immune cells in the brain, except NK cells (Fig. 5, C and J;
p < 0.01), had returned to background levels 5 days after injection into the brain. Furthermore,
Flt3L did not significantly alter any immune cell population in the spleen (Fig. 6), indicating
that increased expression of Flt3L in the brain acts exclusively on local populations of pDCs.

Discussion
Ags localized exclusively within the brain parenchyma, including tumor Ags, fail to prime a
systemic immune response (1–3). This failure of infectious, particulate, or tumor Ags to prime
the immune system is due in part to the absence of afferent professional APCs, such as DCs,
within the naive, noninflamed brain parenchyma. However, DCs have been found in the brains
of MS patients, and this was associated with elevated CCR7 production by myeloid cells
(10). Elevated DC levels in the brain promote the clinical severity of EAE (13), implicating
DCs in the maintenance of chronic immune responses in the brain. Additionally, MHC II
expression exclusively on CD11c+ DCs is permissive for complete EAE induction, indicating
a crucial role for CD11c+ DCs in initiating immune responses against brain Ags. Prolonged
exposure of the immune system to myelin Ag was required for the development of EAE (8),
suggesting that the immune system encounters brain Ag in the absence of chronic
inflammation. This, in turn, implies that DCs or other APCs can encounter brain Ag before
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chronic inflammation. A cell type located within the naive brain, able to pick up Ag and
transport it to the cervical lymph nodes, has not yet been indisputably described.
Flt3L is a cytokine related to c-Kit and stem cell factor that binds to the Flt3R expressed on
immature hemopoietic cells, especially DC precursors (32,33). We have recently shown that
the expression of Flt3L in an intracranial tumor dramatically improved rat survival in an
immune-mediated manner (22). Addition of the cytotoxic gene thymidine kinase was able to
improve long-term survival still further, with 70% of animals surviving for up to 1 year, when
all other viruses tested alone or in combination failed. Depletion of CD4+ T cells and
macrophages completely abrogated these therapeutic effects, highlighting the fundamental role
of Flt3L expression in the brain in stimulating innate and adaptive immune responses against
brain tumor Ag (16). The normal function of Flt3L in the brain is to promote neuronal survival
in combination with nerve growth factor (34) and is expressed by microglia in vitro, although
whether other cells also contribute to the level of endogenous brain Flt3L is not known (35).
We hypothesized that the expression of Flt3L within the brain stimulates the migration of DCs
to brain parenchyma.

Previous work revealed that DCs in the brain are located in the CSF, meninges, and
subarachnoid space (36). We found that the expression of Flt3L in the striatum induced the
infiltration of pDCs into brain parenchyma. We did not observe any evidence of cDCs in brain
parenchyma in response to Flt3L using markers for cDCs by either flow cytometry or confocal
microscopy. Furthermore, other immune cells, including T cells, B cells, NK cells, NKT cells,
and macrophages, were not significantly elevated, suggesting that Flt3L expression within the
brain is acting specifically on the pDC subpopulation. The population of brain-infiltrating
pDCs after the expression of Flt3L appeared to be an immature, lineage-committed pDC. In
support of this, MHC II expression was low and could not be detected in CD45R+ cells
infiltrating the brain when analyzed by confocal microscopy. This is consistent with previously
published descriptions of pDCs, where it has been shown that pDCs isolated from the bone
marrow lack expression of MHC II protein (37). We did, however, detect MHC II mRNA
extracted from purified, brain-derived pDCs, and the levels of expression closely correlated
with those of spleen pDCs. In addition, these cells were not found to express the costimulatory
molecule CD80, indicating that pDCs in the brain had not fully matured into APCs. Immature,
IFN-α-producing pDCs do not express the co-stimulatory molecules CD80 and CD86 and have
been shown to be incapable of driving Ag-specific T cell proliferation (28).

We found that brain-derived pDCs purified from brain tissue homogenate 5 days after the
injection of RAdFlt3L constitutively expressed high levels of IFN-α, a hallmark of activated,
immature pDCs. These cells were refractory to subsequent stimulation with CpG, whereas
IFN-α expression in naive spleen pDCs from the same animals required stimulation with CpG.
It has recently been reported that TLR9 is required for IFN-α expression in pDCs, but after 24
h, IFN-α synthesis becomes refractory to additional stimulation by the same or different viruses
(H. Kanzler, W. Cao, and Y.-J. Liu, unpublished observations; reported in Ref. 28). This was
consistent with our observations and suggests that pDCs infiltrating brain parenchyma in
response to Flt3L are activated to constitutively produce IFN-α (Fig. 7). However, future
studies are required to confirm whether TLR9 stimulation in brain pDCs can create a refractory
phenotype to further TLR9 stimulation.

The presence of immature pDCs has been associated with promoting tolerance to brain Ags.
Freshly isolated human pDCs induce CD4+ T cell anergy (38), and it has been reported that
immature pDCs activated by CpG can differentiate naive T cells into regulatory T cells (39).
Immature pDCs are present in early stages of breast cancer and have been associated with a
marked reduction in survival. These cells are nonactivated pDCs and appear to promote
immune tolerance against tumor Ag (40). However, activated pDCs possess the capacity to

Curtin et al.

Page 10

enhance cDC-mediated T cell activation (28) and can mature into APCs by increasing the
expression of CD40 and CD86 costimulatory molecules and MHC II in response to TLR7 or
TLR9 stimulation (28,41). Mature pDCs with increased MHC II and costimulatory molecule
expression (42) can induce the expansion of CD8+ T cells and Th1-polarized CD4+ T cells
against endogenous Ag (43). Our results indicate that Flt3L alone recruits IFN-α-producing,
immature pDCs into the brain.

Infiltrating pDCs within the brain parenchyma in response to Flt3L may come from a number
of potential sources, including peripheral sites, such as the spleen, or local sites, including the
CSF and meninges, or from differentiation of precursor cells within brain parenchyma. We did
not observe any expansion of peripheral populations of pDCs, suggesting that infiltration of
blood-derived pDCs across the blood-brain barrier was not responsible for the elevated number
of brain DCs in response to Flt3L expression (14). Therefore, local sources of DCs, such as
the meninges and choroid plexus, are more likely sources of pDCs infiltrating the brain (44).
Another potential local source of pDC precursor cells is resident brain microglia. Brain
microglia are derived from precursor monocytes that migrate into the brain during fetal
development (45) and have a very low turnover in adults. Microglia express markers common
to macrophages and DCs and treatment of enriched microglial cultures from healthy adult
mouse brains with GM-CSF and CD40L induced the expansion of DCs, suggesting that cells
that can serve as DC precursors were present in the enriched microglial culture (12) unless the
culture contained the choroids plexus and ventricles, which it most certainly did. Mouse
neonatal microglial cells were demonstrated to express c-Kit, but not Flt3R (46). In addition,
Flt3L neither induced the proliferation of neonatal microglial cells (46) nor stimulated the
differentiation of DCs from adult microglial cells in vitro (12). Consistent with these data, we
did not find any evidence for increased proliferation of microglia within the brain in response
to Flt3L, and the evidence from the literature suggests that microglia are not capable of
differentiating into pDCs in response to Flt3L. However, this does not rule out the presence of
progenitor immune cells within the brain as the source of pDCs.

In conclusion, we have demonstrated that elevated expression of Flt3L induces an increase in
the number of IFN-α-producing, immature pDCs within brain parenchyma. This finding has
important implications in the field of neuroimmunology. By increasing the level of Flt3L within
the brain, we can increase the number of pDCs and stimulate immune responses against foreign
Ags located within the brain, such as tumor Ag (16,22). Our data suggest that it is possible to
recruit pDCs into brain parenchyma by manipulating the brain microenvironment. This opens
up the possibility of manipulating the priming of adaptive immune responses against foreign
Ags from the brain in situ and could, in turn, give rise to novel therapeutic approaches to treat
brain infections or tumors.
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FIGURE 1.

Expression of Flt3L in rat brain using RAdFlt3L. A, Schematic diagram outlining the injection
of RAdFlt3L into rat brain striatum and the subsequent dissection of brain tissue around the
injection site while carefully avoiding ventricles and meninges. B, Human Flt3L ELISA is
specific for recombinant human Flt3L and does not cross-react with recombinant mouse Flt3L.
Rodent Flt3L ELISA does not cross-react with recombinant human Flt3L. C, Human Flt3L
was elevated 20-fold compared with endogenous rat Flt3L in the brain when animals were
injected with RadFlt3L. However, endogenous Flt3L did not change in response to viral
injection into the brain. D, Injection of RAdFlt3L in the brain elevated serum concentrations
of Flt3L 10-fold over those of endogenous rat serum Flt3L, the concentration of which was
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not found to change in response to viral injection. E, HEK 293 cells were plated on coverslips
in 6-well plates at a density of 1.5 × 105 cells/well. The following day, medium was changed,
and cells were transfected with 1 μg of plasmid DNA (pAL119-hsFlt3L, pAL119-hbFlt3L,
pAL119-msFlt3L, or pAL119-mbFlt3L) using GeneJuice (Novatech) according to the
manufacturer’s instructions. After 48 h, cells were fixed in 4% paraformaldehyde for 5 min
and stained for human soluble Flt3L using rabbit anti-Flt3L Ab. Goat anti-rabbit-HRP
secondary Ab and 3,3′-diaminobenzidine were used to visualize Flt3L-expressing cells. F,
Confocal image showing the expression of human Flt3L (green) and GFAP (magenta), NeuN
(red), ED1 (red), or MBP (red), as indicated, within the brain striatum. Double labeling of Flt3L
with GFAP- (white) and MBP (yellow)-expressing cells indicates that the majority of
RAdFlt3L infected astrocytes and oligodendrocytes. Flt3L was not found to colocalize with
NeuN (yellow), suggesting that RAdFlt3L was not expressed in rat neurons. We also observed
double labeling of ED1 and RAdFlt3L by confocal microscopy (yellow). However, transverse
slices revealed that Flt3L does not colocalize with ED1 and was, instead, indicative of contacts
or close association between activated microglia and RAdFlt3L-expressing cells, rather than
actual expression of Flt3L by ED1-positive microglia. Results are representative of five
animals analyzed in each group.
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FIGURE 2.

Intracranial injection of RAdFlt3L increased infiltrating pDC (CD3−CD45R+CD4+), IFN-α
and TLR7 in brain parenchyma. A, Detection of pDC (CD3−CD4+CD45R+) in brain
parenchyma using flow cytometry. B, Detection of CD4+ cDC (CD4+CD11c+CD45high) in
brain parenchyma using flow cytometry. C, Absolute numbers of pDC in brain parenchyma
are elevated 5 days after the injection of RAdhsFlt3L compared with those in control animals
(p < 0.001). D, CD4+ cDCs are not elevated in brain parenchyma of animals 5 days after
intracranial delivery of RAdFlt3L compared with controls (NS, p > 0.05). E, Detection of pDCs
(CD3−CD4+CD45R+; upper panel) and cDCs (CD4+CD11c+CD45high; lower panel) in spleen
using flow cytometry. The percentage of pDCs (F) or cDCs (G) in the spleen did not change
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in response to either Flt3L expression or adenoviral delivery into the brain. Rats were injected
in the striatum with saline (Sa), RAd0 (R0), or RAdFlt3L (FL). RNA was extracted from brain
tissue surrounding the injection site after either 1 or 5 days, and RT-PCR was used to determine
type I IFN (H) and TLR (I) expression. We found that IFN-α (H) and TLR7 (I) were transiently
increased in response to Flt3L expression in the brain compared with saline and RAd0 controls
after 1 day. IFN-β (H) and TLR9 (I) were not altered. Twenty-five cycles of PCR were used
to detect GAPDH, and 30 cycles of PCR were used to detect IFN-α, IFN-β, TLR7, and TLR9
expression. Flow cytometry dot plots (A, B, and E) indicate the cell populations quantified and
are representative of staining observed in 5-day samples. Error bars in C, D, F, and G depict
the SEM.
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FIGURE 3.

Brain-infiltrating pDCs are IFN-producing cells and constitutively express high levels of IFNα. A, Brain mononuclear cells from 30 brain hemispheres treated with RAdFlt3L were pooled
and stained, and 10,000 CD3−CD45R+CD4+ cells were collected. Ten thousand
CD3−CD45R+CD4+ cells were also collected from the spleen. B, We used 40 cycles of PCR
to detect the expression of MHC II and CD80 in unstimulated pDCs isolated from brain or
spleen. Both brain and spleen pDCs expressed MHC II (top panel), but we did not detect any
expression of CD80 (middle panel). GAPDH was also analyzed to demonstrate equal loading
of samples (bottom panel). C, Cells expressing CD45R and MHC II were present in the brains
of rats 5 days after the injection of RAdFlt3L. However, CD45R cells were not found to express
MHC II. D, Some overlap between CD45R and MHC II was found at cell junctions, indicating
close association of the cell membranes. CD45R+/CD4+ cells infiltrated the brain. E and F,
Cells expressing MHC II (red), but not CD45R (green), were observed in intact meninges of
animals 5 days after the expression of either RAd35 (E) or RAdFlt3L (F). The borders of the
meninges are outlined in gray. G, Thirty-five cycles of PCR were used to detect IFN-α and
GAPDH expression in cDNA copies of total RNA isolated from 10,000 purified brain or splenic
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pDCs incubated with 20 μg/ml CpG for 3 h or left untreated. IFN-α was detected in spleen
pDCs only after treatment with CpG (right panel), but was constitutively expressed in pDCs
purified from brain mononuclear cells (left panel). H, Forty cycles of PCR were used to detect
TLR9 and GAPDH expression in purified pDC samples isolated from brain and spleen. pDCs
were incubated with or without 20 μg/ml CpG for 3 h before total RNA was isolated for RTPCR analysis. TLR9 was expressed at lower levels in brain pDCs (left panel) than in
unstimulated spleen-derived pDCs, but was reduced in spleen pDCs after incubation with CpG
(right panel). L, lanes containing DNA ladder.
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FIGURE 4.

Infiltrating CD4+/CD45R+ cells do not express other BCR markers. A, Cells were analyzed
for cell surface Igκ (B) and Igλ (C) expression using flow cytometry. CD45R+CD4+ cells did
not express either Igκ or Igλ. However, some CD4−CD45R+ cells (B cells) were identified that
expressed Igκ(B) or Igλ(C). Data shown are representative of four separate animals.
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FIGURE 5.

Flt3L does not induce infiltration of other immune cells into brain parenchyma. Detection of
CD4+ T cells (CD3+CD4+CD8a−) and CD8+T cells (CD3+CD4−CD8a+; A), B cells
(CD3−CD4−CD45R+; B), NK cells (CD3−CD161a+), and NK-T cells (CD3+CD161a+; C);
microglia (CD45dim; D); and macrophages (CD11b+CD45high; E) in brain parenchyma was
performed using flow cytometry. Acute inflammation 1 day after the injection of either virus
resulted in a significant increase in CD4+ T cells (p < 0.01; F), CD8+ T cells (p < 0.05; G), B
cells (p < 0.05; H), and NK-T cells (p < 0.05; I), suggesting that virus delivery alone transiently
increases immune cells in the brain. NK cells were elevated in all samples 1 day after the
injection of virus or saline (J), suggesting that infiltration occurred in response to tissue damage
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associated with injection trauma. The numbers of microglia (K; p < 0.01) and macrophages
(L; p < 0.01) were elevated in RAd35-injected animals 1 day after injection compared with
saline-injected animals. RAdFlt3L also induced an increase in total macrophages, although
this was not significant (p > 0.05). This acute inflammatory response was transient, and absolute
numbers of CD4+ T cells (F), CD8+ T cells (G), B cells (H), NK-T cells (I), and microglia
(J) had all returned to normal levels after 5 days. NK cells remained slightly elevated in both
RAd35- and RAdFlt3L-injected animals (J), and the number of macrophages was modestly
elevated (NS, p > 0.05) in Flt3L-injected groups after 5 days (L). M, ED1 expression in the
brain (red) was visualized using confocal microscopy. We saw parenchymal macrophages or
activated microglia staining in the brains of rats 5 days after injection of either RAdFlt3L or
RAd35, but not in saline-injected animals (not shown). However, no significant difference was
observed between RAdFlt3L or RAd35, indicating that Flt3L does not increase the total number
of ED1-immunoreactive cells in the brain. The flow cytometry graphs shown in A--E indicate
the cell populations quantified and are representative of staining observed in 5-day samples
injected with RAdFlt3L. Three animals per group were used for all 1 day points and 5 day
points in (F, G, and L). At least seven animals per group were used for all other 5 day points
(H–K). Error bars in F–L depict the SEM. The confocal images shown in M are representative
of five animals analyzed per group.
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FIGURE 6.

Flt3L expression in the brain does not alter populations of immune cells in the spleen. Animals
were injected with saline, RAd35, or RAdFlt3L. After 5 days, the percentages of B cells
(CD3−CD45R+CD4−; A and D), T cells (CD3+CD161a−; B and E), NKT cells
(CD3+CD161a+; B and F), NK cells (CD3−CD161a+; B and G), and macrophages (C and H;
CD4+CD11b+CD45+) within the spleen were assessed. We found that only macrophages
significantly increased in response to RAdFlt3L compared with saline-injected animals.
However, these cells were also elevated in response to RAd35 injected into the brain, indicating
that this was a response to viral delivery and not Flt3L-induced proliferation of macrophages.
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FIGURE 7.

TLR9 signaling in brain- and spleen-derived pDCs. In the absence of CpG, unstimulated pDCs
isolated from the spleen (upper left) expressed TLR9 (1). However, IFN-α was not expressed
in these cells (A, left). After incubation with CpG (upper right), CpG was endocytosed by
spleen pDCs (1) and bound with TLR9 in the endosomal compartment (2). This recruited the
TLR9 signaling complex, comprised of MyD88, IRAK1, and IFN-regulatory factor 7 (IRF7),
to TLR9. Activation of IRAK1 resulted in IRF7 phosphorylation (3) and translocation to the
nucleus (4). IRF7 activates transcription of IFN-α (5), which, in turn, is secreted from the cell
and binds with IFNR1 (6). IFNR1 signaling appears to down-regulate TLR9 expression in
spleen cells shortly after stimulation with CpG (7). The pDCs isolated from the brain after
overexpression of Flt3L (lower left) had lower expression of TLR9 than the naive spleen
counterparts. IFN-α was constitutively expressed (3), presumably through MyD88 and IRF7
(1,2) and was secreted by these cells (4). After incubation with CpG (lower right) (1,2), IFNα was not further increased (3), indicating that TLR9 signaling was refractory to
superstimulation using CpG.

